Using data on snus use in Sweden to compare different modelling approaches to estimate the population health impact of introducing a smoke-free tobacco product

CURRENT STATUS: ACCEPTED

BMC Public Health  •  BMC Series

Peter Lee  PeterLee@pnlee.co.uk
Corresponding Author

Smilja Djurdjevic
Philip Morris International Research and Development Campus Neuchatel

Laszlo Pecze
Independent Consultant

Rolf Weitkunat
Philip Morris International Research and Development Campus Neuchatel

Frank Luedicke
Philip Morris International Research and Development Campus Neuchatel

John Fry
RoeLee Statistics Ltd

DOI: 10.21203/rs.2.10935/v1

SUBJECT AREAS
Epidemiology

KEYWORDS
Smoking, Snus, Modelling, Attributable risk, Smoke-free tobacco product, Harm reduction, Validation
Abstract

Background

We have developed an approach for modelling the health impact of introducing new smoke-free tobacco products. We wished to compare its estimates with those of alternative approaches, when applied to snus, used in Sweden for many years.

Methods

Modelling was restricted to men aged 30-79 years for 1980-2009 and to four smoking-related diseases. Mortality data were extracted for Sweden and other European countries. Published data provided Swedish prevalence estimates for combinations of never/former/current smoking and snus use, and smoking prevalence estimates for other European countries. Approach 1 compares mortality in Sweden and in other countries with a smoking prevalence similar to Sweden’s prevalence of combined smoking/snus use. Approaches 2 and 3 compare mortality in Sweden with hypothetical mortality had snus users smoked. Approach 3 uses our health impact model, individuals starting with the tobacco prevalence of Sweden in 1980. Tobacco histories during 30-year follow-up were then estimated using transition probabilities, with risk derived using a negative exponential model. Approach 2 uses annual tobacco prevalence estimates coupled with estimates of relative risk of current and former smokers regardless of history. The main applications of Approaches 2 and 3 assume that only smoking affects mortality, though sensitivity analyses using Approach 3 allow for risk to vary in snus users and dual users.

Results

Using Approach 2, estimated mortality increases in Sweden in 1980-2009 had snus not been introduced were: lung cancer 8,786; COPD 1,781; IHD 10,409; stroke 1,720. The main Approach 3 estimates were similar (7,931; 1,969; 12,501; 1,901). They decreased as risk in snus users and dual users increased. Approach 1 estimates differed wildly (77,762;
remaining very different following correction for differences between Sweden and the comparison countries in non-smoking-related disease mortality.

Conclusions

Approach 1 is unreliable, accounting inadequately for non-tobacco factors affecting mortality. Approaches 2 and 3 provide reasonably similar approximate estimates of the mortality increase had snus not been available, but have differing advantages and disadvantages. Only Approach 3 considers tobacco history, but develops histories using tobacco transition probabilities, which is possibly less reliable than using estimated tobacco prevalences at each follow-up year.

Background

While quitting tobacco and nicotine altogether is clearly the best way for cigarette smokers to reduce their risk of harm and disease, many will not quit. If cigarette smokers who would otherwise not quit would switch to a reduced smoke-free tobacco product (SFTP), this could be helpful from a harm reduction standpoint, especially if the reduction in risk inherent to their chosen product is substantial. In this regard, various SFTPs have recently been developed, notably e-cigarettes and heat-not-burn products. While evidence from biomarkers of exposure and short-term clinical tests shows that switching to these products (such as a heat-not-burned product, marketed as IQOS) presents less risk than continued smoking, there is currently no reliable evidence of benefit from epidemiological prospective cohort or case-control studies, even though some of these products have been on the market for over five years. Nevertheless, there is a need to estimate the population health impact of introducing SFTPs, partly to satisfy the requirements of the United States Food and Drug Administration’s draft guidelines [1] to applicants seeking to introduce such products into the U.S. market under a modified-risk tobacco product marketing order.
In 2015, we developed an approach to assess the population health impact of introducing a SFTP [2], leading to estimates of the impact of such introduction in the US on mortality from the four main smoking-related diseases (SRDs) - lung cancer, chronic obstructive pulmonary disease (COPD), ischaemic heart disease (IHD) and stroke [3, 4]. The Population Health Impact Model (PHIM) we developed involves starting in a given year with a prevalence of smoking (never, current, former – by time quit) that is representative of the population studied. Individual tobacco histories are updated annually over a defined period using estimated probabilities of switching between never/current/former cigarette smoking where the SFTP is not introduced (the “Null” or “Historical” Scenario), or switching between never/current cigarettes only/current SFTP only/current dual use/former smoking where it is (the “Alternative” or “Hypothetical” Scenario). Based on (a) the tobacco histories obtained, (b) published estimates of the relative risk for current smoking and of the quitting half-life (the time it takes to halve the excess risk associated with continued smoking) [3], and (c) estimates of the effective dose (compared to cigarette only smokers) for SFTP only and for dual use, a negative exponential model (NEM) [3, 5] is used to estimate each individual’s risk of each disease at each year of follow-up.

Combining these estimates with national data on population size and mortality, one can then estimate the expected numbers of deaths in each Scenario and hence the reduction in the number of deaths related to introducing the SFTP.

Due particularly to limited data on the switching probabilities in the Hypothetical Scenario and on the effective dose for exclusive SFTP use and for dual use, such estimates are clearly imprecise. Furthermore, the modelling approach used to estimate the reduction in deaths following SFTP introduction cannot be validated against observed changes in mortality for recently introduced SFTPs.

However, extensive evidence on uptake and risk is available for one SFTP that has been on
the market for many years. This is Swedish moist snuff, commonly referred to as “snus”, which has been marketed in Sweden for over 100 years [6]. Despite published meta-analyses [7-9] showing excess risks of the main SRDs to be much lower than those from cigarette smoking, it is rarely used in most other European countries, as snus is banned for sale outside Sweden in the European Community.

Here we use three approaches to estimate the increase in the number of deaths from the four major diseases that would have occurred in Sweden over the 30-year period starting in 1980 if snus had not been available.

“Approach 1” compares the number of deaths that did occur in Sweden with the number that would have occurred if Sweden had the mortality rates of other European countries with a prevalence of smoking relatively similar to the prevalence of overall tobacco use (for smoking and snus combined) in Sweden.

“Approach 2” compares the number of deaths that did occur in Sweden with the number that would have occurred if current and former snus users had actually been current and former smokers.

While these two approaches do not use the PHIM, “Approach 3” uses it to make a similar comparison to Approach 2.

All three approaches provide estimates of the increase in mortality from the four diseases that would have occurred in Sweden if snus had not been introduced.

**Methods**

**Data used**

All data considered were for males and for the period 1980-2009. Effects on mortality were restricted to those aged 30-79 years.

Annual data by five year age groups on population size for Sweden, and in the case of Approach 2 for other European countries, came from the United Nations website [10].
Annual data by five year age groups for Sweden and other European countries on deaths from lung cancer, chronic obstructive pulmonary disease (COPD), ischaemic heart disease (IHD), stroke (“the four diseases”), all SRDs, all non-smoking-related diseases (NSRD), and all causes combined came from the WHO database [11]. The definition of SRDs was based on that defined by Tachfouti et al [12] with minor modifications, as described in detail in Supplementary File 1.

Published data were used to estimate prevalence for Sweden for nine groups of tobacco use, representing each combination of the 3 x 3 matrix smoker (never/former/current) x snus user (never/former/current), separately for 20 age groups (15, 16, 17, 18, 19, 20, 21-24, 25-29, 30-34 ... 80-84 and 85+). Details of the source publications and the methods used to estimate the prevalences are given in Supplementary File 2.

Other data used were specific to particular approaches and the sources are described below.

Approach 1

In males in 1980-2009 in European countries other than Sweden tobacco users were nearly all cigarette smokers. Approach 1 estimates the effect of snus use in Swedish males based on a comparison of their mortality rates with those seen in combined male data from other European countries with an overall prevalence of current tobacco use similar to that in Sweden. Comparisons were made annually from 1980 to 2009 of mortality from the four diseases for the combined age group 30-79 years with age-standardization to the European standard population (ESP 1976) [13].

For Sweden the overall prevalence of current tobacco use in each year for each age group was estimated by combining all those estimated prevalences for the nine tobacco use groups described above which involved current smoking and/or current snus use.

Annual data on the prevalence of current smoking for European countries was extracted
from the Global Burden of Disease Study 2015 [14], although data for countries with an average population size less than 500,000, with sales of tobacco products other than manufactured cigarettes or snus greater than 35%, or with markedly incomplete mortality data were not considered. Countries were considered similar to Sweden if the average annual absolute difference between their prevalence and that in Sweden for 1980-2009 was less than 4%.

For each five year age group, annual mortality rates (per 100,000) for each of the four diseases and countries were then calculated by dividing estimates of the numbers of deaths by estimates of the population size [10] and multiplying by 100,000. Weights calculated from the ESP 1976 [13] for each five year age-group then provided the age-standardized mortality rates. For each disease, year and country, these were divided by the corresponding value for Sweden to give the disease specific mortality rate ratios (normalized to Swedish data).

For each disease, year and country, the number of deaths in Sweden occurring at age 30-79 years was then multiplied by the corresponding rate ratio to obtain the hypothetical number of deaths that would have occurred with the mortality rate of the comparison country. The mean of these hypothetical numbers of deaths was then compared with the actual number of deaths that occurred in Sweden.

As mortality in Sweden may be lower than that in other countries for reasons other than tobacco use, adjusted hypothetical numbers of deaths were also calculated. The method was as described in the previous paragraph except that the year- and country-specific rate ratios used to multiply deaths in Sweden for each of the four diseases were each divided by the corresponding rate ratio calculated for deaths from all NSRD.

The differences between the hypothetical numbers (adjusted or unadjusted) of deaths in Sweden and the numbers actually occurring are indicators of the increase in deaths that
would have occurred in Sweden had snus not been on the market.

Approach 2

As for Approach 1, Approach 2 estimates a counterfactual mortality rate for Swedish males assuming that snus was not available and that those who had used snus smoked instead. Approach 2 compares numbers of deaths in males aged 20-79 years from a specified disease that occurred in Sweden in a defined year (situation A) with the number that would have occurred if snus users had smoked cigarettes instead (situation B), the difference (B-A) being an estimate of the increase in deaths that would have occurred if snus had not been available.

The estimation required annual age-specific data for Swedish males on tobacco use prevalence for the nine categories as described earlier, population size [10] and numbers of deaths for the diseases of interest [11]. It also required estimates of relative risks of the four diseases for current and former smokers. These estimates, shown in Table 1, came from published meta-analyses [3, 15, 16]. Table 1 also includes estimates of relative risks for current snus use, again taken from a published meta-analysis [8]. As can be seen the relative risks for current snus use were all non-significant and close to 1, so it was decided to estimate mortality assuming that disease risk depends only on smoking.

Table 1. Relative risks of tobacco related disease in Swedish males

Table 1 presents relative risks for lung cancer, COPD, IHD and stroke for current and former smokers compared to never smokers and for current snus users relative to never users. Estimates for IHD and stroke for smoking are given by age, but other relative risks are assumed to be independent of age. The estimates for smoking come from published meta-analyses for lung cancer [15], for COPD [16], and for IHD and stroke [3]. The estimates for snus use come from another published meta-analysis [8].

If one subdivides the population into nine groups, one can compare risk in the alternative
situations, as summarized in Table 2. Note that death rates in situations A and B are identical in six of the nine groups, differing only for groups 4, 7 and 8.

Table 2. Estimating death rates in Approach 2

For the nine tobacco use groups, Table 2 shows the death rates that would apply in Situation A, which concerns the number of deaths in males from a specified disease that did occur in Sweden in a defined year, and in situation B, which concerns the number that would have occurred in that year if snus users had smoked cigarettes instead. N is the death rate in never smokers, F is that in former smokers and C is that in current smokers. The estimation, which was carried out separately for different five year age groups, with the results then combined over age group, requires estimates for each year of the population size in each group, N, and of the total number of deaths from the disease of interest, D.

Given the proportions in the nine groups, (Pi, i = 1 ..... 9) and the relative risk of disease for former smokers and current smokers compared to never smokers, RF and RC we first estimated the death rate in never smokers, U, from the formula

\[ U = D / [N (P1 + P2 + P3 + RF (P4 + P5 + P6) + RC (P7 + P8 + P9))] \]

The number of deaths in each group in situation A was then obtained by multiplying N*U*Pi by 1 for groups 1 to 3, RF for groups 4 to 6 and by RC for groups 7 to 9. The number of deaths in each group in situation B is the same as that in situation A in six groups (1, 4, 5, 7, 8, 9) but is multiplied by RF for group 2, RC for group 3 and RC/RF for Group 6.

Approach 3

The methodology of the PHIM, which was designed to assess the population-level health impact of marketing a SFTP, has already been summarized in the background section and is described in more detail elsewhere [2, 3]. The application of the PHIM used in Approach
3 involves comparison of mortality from the four main SRDs in two scenarios, a “historical” scenario (SNUS) in which snus is present and a “hypothetical” scenario (NO-SNUS) in which the snus is not present. In each scenario tobacco transition probabilities (TTPs) determine the rate at which individuals change tobacco groups. Based on the tobacco use histories built up, the relative risks of each disease are then estimated for each individual, and are used to determine the number of deaths attributable to tobacco. The difference between the estimated numbers of deaths for the two scenarios (NO-SNUS minus SNUS) then provides the increase in mortality if snus had not been available.

In Approach 3, simulated samples of 100,000 males start in 1980 with a distribution of smoking habits consistent with the prevalence in Swedish males in that year.

In the SNUS scenario individuals start in five groups – never tobacco (representing the combination of groups 1 + 2 of the original nine groups shown in Table 2), current cigarettes only (7 + 8), current snus only (3), current dual use (9) and former tobacco (4 + 5 + 6). This was based on two assumptions. One was that there was no increase in risk associated with former use of snus, consistent with epidemiological evidence that exclusive snus use is associated with little or no increase in the incidence of the smoking attributable diseases studied [8, 9]. This suggests that any risk of former snus use can be ignored, so indicating that groups 1 + 2, 4 + 5 and 7 + 8 could each be combined as having equivalent risk. Evidence that current snus users who formerly smoked (“switchers”) have risks very similar to those of never users who quit smoking (“quitters”) [17] also justified the decision to count those originally in group 6 as having equivalent risk to the other former cigarette smoking groups 4 and 5.

In the NO-SNUS scenario, individuals start in three groups again based on the original nine groups – never cigarettes (1), former cigarettes (2 + 4 + 5) and current cigarettes (3 + 6 + 7 + 8 + 9). Thus, this scenario included as former smokers all those who had used
either or both products but did not currently use them, and as current smokers all those who were current users of either or both product. Never smokers included only those who had never used either product. Effectively it was assumed that cigarette smoking totally replaced snus use.

During each year of the 30 year follow-up period (1980-2009), individuals can switch groups according to defined TTPs. In the SNUS scenario there are 15 TTPs, three relating to initiation, three relating to quitting, three relating to re-initiation and six relating to switching. Thus, for example, individuals may initiate or re-initiate to each of the three current use groups, or may quit from each of them. In the NO-SNUS scenario there are three TTPs, representing initiation, quitting and re-initiation. The values of the TTPs used, which are age dependent, are given in Supplementary File 3 which also provides further details of the methodology. Note that the TTPs for initiation and re-initiation in the NO-SNUS scenario are the same as the three TTPs in the SNUS scenario, while the TTPs for quitting in NO-SNUS are the same as the three identical TTPs for quitting in SNUS.

Comparison is between mortality in the two scenarios over the 30 year follow-up period. Note that any individual reaching age 80 drops out of the population, so by the end of follow-up smoking prevalence refers to those aged 40–79. The model requires the disease and age-specific estimates of the relative risk associated with continued smoking, and also requires estimates of the quitting half-life, the time after quitting when the increase in relative risk associated with smoking has halved. These estimates, derived from published meta-analyses, are provided in our earlier paper [3], which clarifies the sources used.

The model also requires estimates of the “relative exposure” (RE) corresponding to the current tobacco use pattern. This takes the value 0 for an individual not using tobacco (a never or former user), 1 for a current cigarette smoker, f for a current SNUS user (the f-
factor), and g for a dual user (the g-factor), a dual user being an individual whose tobacco use pattern consists of a substantial use of both cigarettes and snus. The results shown in Table 1 suggest that the f-factor is close to zero and the g-factor is close to 1. In Approach 2 and in the main analysis using Approach 3, we assume that f = 0 and g = 1. In Approach 3 we also conduct sensitivity analyses, with g = 1 and f = 0.1 or 0.2, and with f = 0 and g = 0.9, 0.8 or 0.5.

For each of the four major SRDs and for each five-year age group and each year of follow-up the PHIM estimates the mean relative risk for each of the two scenarios. The number of deaths occurring in the SNUS scenario is the number that actually occurred, while the number occurring in the NO-SNUUS scenario can be obtained by multiplying this number by the ratio of the mean relative risks in the NO-SNUUS and SNUS scenarios. The difference between these two numbers of deaths is then the required increase in deaths for that disease, age group and year.

Results

Tobacco use prevalence in Swedish male population

Figure 1 shows the distribution of prevalence of tobacco use in Swedish males for the nine categories by year for the age-groups 30-79, 30-34, 50-54 and 70-74 years. Cigarette smoking prevalence, standardized to age 30-79 years, declined from 33% in the 1980s to 11% in the 2010s (red and brown areas). Over the same period, the prevalence of snus users including snus and cigarette dual use increased from 11% to 23% (green and brown areas). Fewer former smokers and former snus users are observed at younger ages, as expected. Nevertheless, the prevalence of former tobacco users also decreased during the observed period. Consequently, the subcategory of never tobacco users increased with time.

Figure 1. Distribution of tobacco use status in Swedish males by year and age
Figure 1 shows the distribution of the nine subcategories of tobacco use status in Swedish males by year from 1980-2009 for all ages (30-79 years), and for three selected age groups.

Approach 1

There were seven other European countries where, over the period 1980-2009, the mean absolute difference between their age-standardized prevalence of current smoking in males aged 30-79 years differed from the prevalence of current tobacco use for Sweden by less than 4%. These countries, with the mean absolute differences from Sweden shown in parentheses, were Spain (1.34%), Hungary (1.46%), Lithuania (2.16%), Czech Republic (2.95%), Poland (3.09%), Denmark (3.36%) and Slovakia (3.93%).

Figure 2 shows (blue lines) the number of deaths occurring each year in Swedish males aged 30-79 years from each of the four diseases individually, and also from all SRDs combined and from all NSRDs. Also shown are the hypothetical number of deaths that would have occurred if Swedish males had had the average rates seen in the eleven countries with similar rates of tobacco use, either with adjustment for rates of all NSRD being higher in Sweden (green lines) or without adjustment (red lines). The hypothetical rates are higher, except for IHD in the early years. These results are consistent with the beneficial effect of Swedish snus on population health shown in Table 1. Table 1 in Supplementary File 4 presents the detailed results for the four diseases summarized in Figure 1, expressed as the increase in deaths that would have been seen, if Sweden had the mortality rates of other countries.

Figure 2. Approach 1. Comparison of observed deaths in Sweden with unadjusted and adjusted hypothetical deaths
For the period 1980-2009, Figure 2 compares the numbers of deaths occurring in Swedish males aged 30-79 years (blue lines) with those that would have occurred had they the average mortality of seven other European countries with a prevalence of cigarette smoking similar to the prevalence of tobacco use seen in Sweden. Rates are shown with adjustment (green lines) or without (red lines). Adjustment is based on the lower mortality from all NSRD in Sweden.

Approach 2.

In this approach, deaths actually occurring in Sweden are compared with those that would have occurred if current and former snus users had been current and former cigarette smokers, with a resultant increase in risk. As shown in Figure 3, we observe increased mortality rates in the hypothetical scenario for each disease. The elevation is clear for lung cancer and COPD, but still evident for IHD and stroke. Details of the increase in the number of deaths that would have occurred in Sweden in the absence of snus are shown in Table 2 in Supplementary File 4.

Figure 3. Approach 2. Comparison of observed deaths in Sweden with those in the hypothetical scenario

For the period 1980-2009, Figure 3 compares the number of deaths occurring in Swedish males aged 30-79 years (blue lines) compared with those that would have occurred if the current and former snus users had been current and former cigarette smokers (red lines).

Approach 3.

Figure 4 (historical scenario) and Figure 5 (hypothetical scenario) compare the tobacco use prevalence estimates for Sweden derived as described in Supplementary File 2 with those estimated by the PHIM based on the initial prevalences and the TTPs. The correspondence between the pairs of estimates for current smokers, snus users, and dual
users appears quite reasonable. However, the prevalence of former smokers is overestimated by the PHIM simulations.

Figure 4. Approach 3. Comparison of published and PHIM simulated tobacco prevalence where snus is used.

For the period 1980-2009 and for three age groups, Figure 4 compares tobacco use prevalence in Swedish males based on published data with that estimated from PHIM simulations for the historical scenario, where snus is used.

Figure 5. Approach 3. Comparison of published and PHIM simulated smoking prevalence where snus is not used.

For the period 1980-2009 and for three age groups, Figure 5 compares smoking prevalence in Swedish males based on published data with that estimated from PHIM simulations for the counterfactual scenario, where snus is not used.

Two sets of analyses comparing the historical and hypothetical scenarios were carried out. In the first set, analyses were carried out with the g-factor (relative exposure for dual users) fixed at 1, but with the f-factor (relative exposure for snus only users) varying with values of 0, 0.1 and 0.2. Figure 6 compares the increases in deaths that would have occurred in the hypothetical scenario for these three Approach 3 analyses as well as showing the corresponding estimates using Approach 2. The estimates from Approach 3 with f = 0 are, somewhat lower over the whole follow-up period than those from Approach 2 for lung cancer, and somewhat higher for the other three diseases. As the f-factor increases the estimates from Approach 3 decline for all four diseases, so getting closer to those from Approach 2 for COPD, IHD and stroke and less close for lung cancer.

In the second set, analyses were carried out with the f-factor fixed at 0, but with the g-
factor varying with values of 0.9, 0.8 and 0.5. Figure 7 compares the increase in deaths for these three Approach 3 analyses with those using Approach 2. As the g-factor decreases, the estimates from Approach 3 increase for all four diseases, so getting less close to those from Approach 2 for COPD, IHD and stroke. For lung cancer decreasing the g-factor leads to the increase rising to exceed that from Approach 2.

Table 3 (f-factor) and Table 4 (g-factor) of Supplementary File 4 provide further detail.

Figure 6. Increase in deaths had snus not been introduced compared in Approaches 2 and 3 (varying f-factor)

For the period 1980-2009, Figure 6 compares the increases in deaths that would have occurred in Swedish males had snus not been introduced, as estimated from Approach 2 and from PHIM simulations with the f-factor varying but the g-factor fixed at 1.0.

Figure 7. Increase in deaths had snus not been introduced compared in Approaches 2 and 3 (varying g-factor)

For the period 1980-2009, Figure 7 compares the increases in deaths that would have occurred in Swedish males had snus not been introduced, as estimated from Approach 2 and from PHIM simulations with the g-factor varying but the f-factor fixed at 0.

Comparisons of the increases in deaths associated with unavailability of snus from the different approaches are summarized in Table 3, based on the period 1980-2009. They indicate that for lung cancer and COPD the highest estimates are from Approach 1 and the lowest from Approach 3. For IHD, the adjusted result for Approach 1 is unreliable (the occurrence of IHD being extremely high in Sweden compared to other countries, mostly due to non-smoking attributable cases). Nevertheless, Approach 2 and Approach 3 provide consistent results. For stroke, Approach 1 shows a very large increase in deaths compared to the other approaches.
Table 3. Increase in deaths in Sweden if snus had not been introduced – summary of results

Table 3 shows the increase in the number of deaths that would have occurred in Swedish males aged 30-79 years if snus had not been introduced, as estimated by the different Approaches.

Discussion

In Sweden in 1925, sales of snus represented over two-thirds of total tobacco sales by weight [6]. Though this declined, steadily, to about 20% in 1965, it then increased and currently forms over half of all tobacco sales [6]. There is also evidence of an increasing uptake in Norway in recent years [6]. There is extensive epidemiological evidence that any risks of disease associated with snus use are very much less than those associated with smoking [8].

Here we investigate various approaches [9] for estimating how many more deaths from the four main SRDs there might have been in Sweden in the period 1980-2009 if snus had not been available. Three approaches have been used.

In the first, Approach 1, we compare the number of deaths from the four diseases that occurred in Sweden with the number that hypothetically might have occurred if mortality rates there had been the average of those seen in seven other European countries with an overall prevalence of tobacco use very similar to that seen in Sweden. Because mortality rates in Sweden might also differ from those for the comparison countries for NSRD, we adjusted the hypothetical number of deaths to reflect this. While the difference between the adjusted hypothetical number of deaths and the actual historical number is generally consistent with the reduced risks for snus compared to smoking, interpretation of this difference is far from straightforward. Differences in mortality between Sweden and the comparison countries may arise for various reasons. These may include differences in
exposure to risk factors other than smoking, in healthcare, and in diagnosis and detection of disease. Such differences are likely to vary by disease. Because of this, an adjustment based on diseases unrelated to smoking may well be inaccurate, so that even after adjustment the difference between the actual and hypothetical numbers of deaths will not solely reflect the fact that males in the comparison countries do not use snus.

In Approach 2, we compare the number of deaths occurring in Sweden (situation A) with those that would have occurred if current snus users who were never or former smokers had been current smokers, and if former snus users who had never smoked had been former smokers (situation B). While Approach 2 seems likely to give a better estimate than Approach 1 of the effect that snus use has had on the mortality of Swedish men, some points should be noted. The first is the assumption that Swedish men who used snus but did not smoke would have smoked instead if snus was not available. While not readily testable, one can note that over the period 1965-2005, when the combined sales of snuff and cigarettes (by weight) varied little in Sweden, the proportion of snus rose markedly (Table 4), which seems consistent with this assumption.

Table 4 shows trends in sales of cigarettes and snus (in tonnes) in Sweden over the period 1965 to 2005, together with the percentage of the total from each. Data from [6].

Secondly, our estimates of the prevalence of smoking and snus use over the 30 year follow-up period may be subject to some error. As is clear from Supplementary File 2, estimating prevalences for the nine groups representing combinations of never/former/current smoking and never/former/current snus use for each year from a variety of sources was far from straightforward.

A third point is that the analysis does not take account of the theoretical possibility that
taking up smoking (as an alternative to using snus) may affect exposure to other risk factors.

A final point is that the analysis does not take into account any reduction in population size that would have occurred in situation B. However, this is not unusual in such analyses which estimate the change in mortality that would have occurred in a particular year, given the same population and different assumptions.

Like Approach 2, Approach 3 compares the number of deaths occurring in Sweden with those that would have occurred in the absence of snus. Here, however, this is estimated using the PHIM. In comparing results from Approach 3 with those in Approach 2, various points have to be considered.

First, while Approach 2 estimates deaths occurring at age 30-79 years over the whole follow-up period, individuals in Approach 3 start at age 10-79 years but age during follow-up, so that by the end of the 30 year follow-up period there are none under age 40 years. Since the great majority of deaths from the four diseases occur at age 40 or over, this should make little difference to the comparison.

Second, while in 1980 both Approaches start with the same prevalence of tobacco habits, the prevalences differ in subsequent years. Approach 2 uses prevalence estimates derived from published sources (see Supplementary File 2) while Approach 3 derives prevalence estimates using TTPs. While these simulated distributions of tobacco habits align approximately with the estimates used in Approach 2, there are some differences, as seen in Figures 4 and 5. While it would be possible to define a more detailed set of TTPs which change every year so that the distributions agree better, this would be inconsistent with the usual applications of the PHIM, where TTPs for a new SFTP cannot be precisely known.

In any case, as noted above, the prevalence of estimates used in Approach 2 may themselves be subject to error. Although the methods used to derive prevalence estimates
in the two approaches differ, we do not believe that this is the main reason why the estimated increase in deaths shown in Table 3 vary. This is because the ratio of the estimated increases in the two Approaches varied little between 1980, when the distributions of tobacco were constrained to be the same (Approach 2/Approach 3 1.11 for lung cancer, 0.88 for COPD, 0.83 for IHD and 0.89 for stroke) and 2009 when the differences were most evident (Approach 2/Approach 3 1.10 for lung cancer, 0.90 for COPD, 0.79 for IHD and 0.85 for stroke).

The main reason why the estimates differ between Approach 2 and 3 lies in differences in how the relative risks are calculated. In Approach 2 the relative risks for current and former smokers used, shown in Table 1, are applied assuming that they apply regardless of any aspect of previous smoking history, including duration of smoking or time quit. In contrast, Approach 3 uses the NEM in which the relative risks for current smokers approach the estimates shown in Table 1 with increasing time smoked, while those for former smokers decline from the current smoker relative risk with increasing time quit. Also the NEM takes into account changes in relative risk relating to more complex patterns of smoking history, such as quitting, then re-initiation. Relative risks for short-term quitters may be much higher than assumed in Approach 2, especially for diseases such as lung cancer with a long half-life.

In Approach 2, it is assumed that snus use does not affect risk of the four diseases. This is equivalent to the Approach 3 analyses where the f-factor is set as 0 and the g-factor at 1. As expected, increasing the f-factor increased the number of tobacco-associated deaths in the snus scenario by increasing risk in the group currently using snus only, so decreasing the estimated increase comparing the NO-SNUS and SNUS scenarios. Similarly, decreasing the g-factor decreased tobacco-associated deaths in the SNUS scenario by decreasing risk in the group currently using both products, so increasing the estimated increase
comparing the scenarios. As the Approach 2 estimate cannot be considered to be a gold standard, however, one cannot validly determine which are the most appropriate values of the f- and g-factors by determining those values which produce the estimated increases that are most consistent with those estimated by Approach 2. One must rely on epidemiological evidence to give plausible estimates of the two factors.

**CONCLUSIONS**

Three approaches have been investigated in an attempt to determine the increase in the number of deaths from lung cancer, COPD, IHD and stroke that might have occurred in Swedish men in 1980-2008 if snus had not been available. Approach 1, which compared death rates in Sweden with those in seven other European countries with a similar prevalence of tobacco use produced very different answers from the other two approaches and must be regarded as unreliable as failing to account properly for a range of factors other than tobacco use. Approaches 2 and 3, which both compare the number of deaths occurring in Sweden with the number that would have occurred if current and former snus users had actually been current and former smokers, produced relatively similar results. Approach 3, which uses the PHIM, allows for relative risks to vary based on a detailed tobacco history, may have advantages over Approach 2, in which fixed relative risks are used for current and former smokers, regardless of tobacco history. However, whereas Approach 2 derives tobacco prevalence estimates at each year of follow-up from published statistics, Approach 3, which was developed to estimate the impact of a new SFTP where future prevalence is unknown, derives the estimates using TTPs which may not be accurately determined. Both Approach 2 and 3 can be regarded as reasonable approximate approaches, with different advantages and disadvantages.

List Of Abbreviations
Declarations

Ethics approval and consent to participate not applicable

Consent for publication not applicable

Availability of data and material The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Competing interests JF and PL are independent consultants in statistics and advisers in epidemiology to a number of tobacco companies. LP is a former employee and the all other three authors are current employees of Philip Morris International.

Funding All the work described in the paper was funded by Philip Morris Products SA. The authors are wholly responsible for the design of the study, conduct of the analyses, interpretation of the results, and writing the manuscript.

Authors’ contributions LP and SD conceived the idea of the three approaches, which were discussed with RW, JF and PL. LP and JF carried out all the analyses with the guidance of SD and PL. PL drafted the paper which was then finalized in discussions with the other authors.

Acknowledgements We thank Philip Morris Products SA for financial support, and also Mrs
Y Cooper and Mrs D Morris for typing the various drafts of the paper.

References

1. Food and Drug Administration. Guidance for Industry: Modified Risk Tobacco Product Applications. Draft Guidance. Guidance for Industry: U.S. Department of Health and Human Services Food and Drug Administration Center for Tobacco Products; 2012.

2. Weitkunat R, Lee PN, Baker G, Sponsiello-Wang Z, González-Zuloeta Ladd AM, Lüdicke F. A novel approach to assess the population health impact of introducing a modified risk tobacco product. Regul Toxicol Pharmacol 2015;72:87-93. doi:10.1016/j.yrtph.2015.03.011.

3. Lee PN, Fry JS, Hamling JF, Sponsiello-Wang Z, Baker G, Weitkunat R. Estimating the effect of differing assumptions on the population health impact of introducing a Reduced Risk Tobacco Product in the USA. Regul Toxicol Pharmacol 2017;88:192-213.(Epub 20170623): doi:10.1016/j.yrtph.2017.06.009.

4. Djurdjevic S, Lee PN, Weitkunat R, Sponsiello-Wang Z, Ludicke F, Baker G. Modeling the population health impact of introducing a modified risk tobacco product into the U.S. market. Healthcare (Basel) 2018;6(2):47; doi: 10.3390/healthcare6020047.(Epub 20180516): doi:10.3390/healthcare6020047.

5. Lee PN, Hamling J, Fry J, Forey B. Using the negative exponential model to describe changes in risk of smoking-related diseases following changes in exposure to tobacco. Advances in Epidemiology 2015;Article ID 487876, 13 pages. doi:10.1155/2015/487876.

6. Forey B, Hamling J, Hamling J, Thornton A, Lee P. International Smoking Statistics. A collection of worldwide historical data. (Web edition). Sutton, Surrey: P N Lee Statistics and Computing Ltd; 2006-2016. Available: www.pnlee.co.uk/iss.htm.

7. Lee PN, Hamling JS. Systematic review of the relation between smokeless tobacco and cancer in Europe and North America. BMC Med 2009;7:36. doi:10.1186/1741-7015-7-36.
8. Lee PN. Summary of the epidemiological evidence relating snus to health. Regul Toxicol Pharmacol 2011;59(2):197-214. doi:10.1016/j.yrtph.2010.12.002.

9. Lee PN. Epidemiological evidence relating snus to health - an updated review based on recent publications. Harm Reduct J 2013;10(1):36. doi:10.1186/1477-7517-10-36.

10. United Nations Department of Economic and Social Affairs. World population prospects: the 2012 revision. Excel tables - population data. United Nations, Department of Economic and Social Affairs, Population Division, Population Estimates and Projections Section; 2013. Available: http://esa.un.org/wpp/Excel-Data/population.htm; http://esa.un.org/unpd/wpp/Documentation/pdf/WPP2012_HIGHLIGHTS.pdf; http://www.un.org/en/development/desa/population/publications/pdf/trends/WPP2012_Wallchart.pdf.

11. World Health Organization. WHO mortality database. 2013. Available: http://www.who.int/healthinfo/statistics/mortality_rawdata/en/index.html; http://www.who.int/healthinfo/statistics/mortality_rawdata/en/index1.html.

12. Tachfouti N, Raherison C, Obtel M, Nejjari C. Mortality attributable to tobacco: review of different methods. Arch Public Health 2014;72(1):22.(Epub 20140701): doi:10.1186/2049-3258-72-22.

13. Waterhouse J, Muir C, Correa P, Powell J. Cancer incidence in five continents. vol. III. Lyon, France: International Agency for Research on Cancer; 1976.

14. G. B. D. Tobacco Collaborators. Smoking prevalence and attributable disease burden in 195 countries and territories, 1990-2015: a systematic analysis from the Global Burden of Disease Study 2015. Lancet 2017;389(10082):1885-906.(Epub 20170405): doi:10.1016/s0140-6736(17)30819-x. Erratum appears in Lancet 2017 Oct 7; 390(10103): 1644.

15. Lee PN, Forey BA, Coombs KJ. Systematic review with meta-analysis of the
epidemiological evidence in the 1900s relating smoking to lung cancer. BMC Cancer 2012;12:385. doi:10.1186/1471-2407-12-385.

16. Forey BA, Thornton AJ, Lee PN. Systematic review with meta-analysis of the epidemiological evidence relating smoking to COPD, chronic bronchitis and emphysema. BMC Pulm Med 2011;11:36. doi:10.1186/1471-2466-11-36.

17. Lee PN. The effect on health of switching from cigarettes to snus - a review. Regul Toxicol Pharmacol 2013;66(1):1-5.

Tables

Table 1. **Relative risks of tobacco related disease in Swedish males**

| Age range | Relative Risk (95% CI) Current smoker | Relative Risk (95% CI) Former smoker | Relative Risk (95% CI) Current snus |
|-----------|---------------------------------------|--------------------------------------|-------------------------------------|
| Lung Cancer | Any | 8.68 (7.14-10.54) | 2.62 (2.01-3.42) | 0.80 (0.60-1.06) |
| COPD | Any | 3.31 (2.80-3.92) | 1.99 (1.76-2.25) | 0.80 (0.40-1.60) |
| IHD | to 54 | 3.38 (2.92-3.91) | 1.36 (1.21-1.53) | 1.01 (0.91-1.12) |
| | 55 to 64 | 2.32 (2.05-2.62) | 1.38 (1.22-1.55) | |
| | 65 to 74 | 1.70 (1.56-1.86) | 1.25 (1.16-1.34) | |
| | 75 to 79 | 1.27 (1.21-1.33) | 1.16 (1.08-1.25) | |
| Stroke | Any | 2.48 (1.94-3.17) | 1.10 (0.90-1.34) | |
| | to 54 | 2.13 (1.93-2.34) | 1.17 (1.01-1.36) | |
| | 55 to 64 | 1.39 (1.23-1.58) | 1.15 (1.04-1.26) | |
| | 65 to 74 | 1.06 (0.96-1.17) | 1.00 (0.89-1.12) | |
| | 75 to 79 | 1.04 (0.92-1.17) | | |

Table 1 presents relative risks for lung cancer, COPD, IHD and stroke for current and former smokers compared to never smokers and for current snus users relative to never users. Estimates for IHD and stroke for smoking are given by age, but other relative risks are assumed to be independent of age. The estimates for smoking come from published meta-analyses for lung cancer [15], for COPD [16], and for IHD and stroke [3]. The estimates for snus use come from another published meta-analysis [8].

Table 2. **Estimating death rates in Approach 2**

| Group | Smoking | Snus use | Death rate in situation | A | B | Difference |
|-------|---------|----------|-------------------------|---|---|-----------|
| 1 | Never | Never | N | N | None |
| 2 | Never | Former | N | F | Higher in B |
| 3 | Never | Current | N | C | Higher in B |
| 4 | Former | Never | F | F | None |
| 5 | Former | Former | F | F | None |
| 6 | Former | Current | F | C | Higher in B |
| 7 | Current | Never | C | C | None |
| 8 | Current | Former | C | C | None |
| 9 | Current | Current | C | C | None |

For the nine tobacco use groups, Table 2 shows the death rates that would apply in Situation A, which concerns the number of deaths in males from a specified disease that did occur in Sweden in a defined year, and in situation B, which concerns the number that
would have occurred in that year if snus users had smoked cigarettes instead. \( N \) is the death rate in never smokers, \( F \) is that in former smokers and \( C \) is that in current smokers.

Table 3. Increase in deaths in Sweden if snus had not been introduced - summary of results

|                  | Lung cancer | COPD  | IHD   | Stroke |
|------------------|-------------|-------|-------|--------|
| Approach 1       | 77762       | 32538 | 77438 | 76946  |
| Approach 1 (Adjusted) | 28535     | 11265 | -50597| 23146  |
| Approach 2       | 8786        | 1781  | 10409 | 1720   |
| PHIM \( f = 0.0, g = 1.0 \) | 7931        | 1969  | 12501 | 1901   |
| PHIM \( f = 0.1, g = 1.0 \) | 7423        | 1868  | 11784 | 1781   |
| PHIM \( f = 0.2, g = 1.0 \) | 6932        | 1770  | 11082 | 1663   |
| PHIM \( g = 0.9, f = 0.0 \) | 8367        | 2072  | 13110 | 1986   |
| PHIM \( g = 0.8, f = 0.0 \) | 8812        | 2175  | 13724 | 2072   |
| PHIM \( g = 0.5, f = 0.0 \) | 10198       | 2493  | 15597 | 2333   |

Table 3 shows the increase in the number of deaths that would have occurred in Swedish males aged 30-79 years if snus had not been introduced, as estimated by the different Approaches.

Table 4. Sales of cigarettes and snus in Sweden from 1965 to 2005

| Year | Consumption (tonnes) | Percentage |
|------|----------------------|------------|
|      | Cigarettes | Snus | Total  | Cigarettes | Snus |
| 1965 | 8160       | 2490 | 10650  | 76.6   | 23.4 |
| 1975 | 7587       | 2943 | 10530  | 72.1   | 27.9 |
| 1985 | 7249       | 4560 | 11809  | 61.4   | 38.6 |
| 1995 | 5280       | 5407 | 10687  | 49.4   | 50.6 |
| 2005 | 4499       | 6561 | 11060  | 40.7   | 59.3 |

Table 4 shows trends in sales of cigarettes and snus (in tonnes) in Sweden over the period 1965 to 2005, together with the percentage of the total from each. Data from [6]

Figures
Figure 1

Distribution of tobacco use status in Swedish males by year and age
Figure 2

Approach 1. Comparison of observed deaths in Sweden with unadjusted and adjusted hypothetical deaths
Approach 2. Comparison of observed deaths in Sweden with those in the hypothetical scenario.

Approach 3. Comparison of published and PHIM simulated tobacco prevalence where snus is used.
Approach 3. Comparison of published and PHIM simulated smoking prevalence where snus is not used.

Increase in deaths had snus not been introduced compared in Approaches 2 and 3 (varying f-factor)
Figure 7

Increase in deaths had snus not been introduced compared in Approaches 2 and 3 
(varying g-factor)

Supplementary Files

This is a list of supplementary files associated with the primary manuscript. Click to download.

SnusModellingPaper_Supplementary File 1_V3.docx
SnusModellingPaper_Supplementary File 3_V3.docx
SnusModellingPaper_Supplementary File 4_V3.docx
SnusModellingPaper_Supplementary File 2_V3.docx